Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial

Staples, 1998, Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect?, Int J Cancer, 78, 144, 10.1002/(SICI)1097-0215(19981005)78:2<144::AID-IJC3>3.0.CO;2-Z McCormack, 1997, Differences in age and body site distribution of the histological subtypes of basal cell carcinoma: a possible indicator of differing causes, Arch Dermatol, 133, 593, 10.1001/archderm.1997.03890410049006 Drake, 1992, Guidelines for care of basal cell carcinoma, J Am Acad Dermatol, 26, 117, 10.1016/S0190-9622(08)80524-5 Cornell, 1990, Intralesional interferon therapy for basal cell carcinoma, J Am Acad Dermatol, 23, 694, 10.1016/0190-9622(90)70276-N 1997, Cancer in Australia, 6 Beutner, 1998, Treatment of genital warts with an immune response modifier (imiquimod), J Am Acad Dermatol, 38, 230, 10.1016/S0190-9622(98)70243-9 Beutner, 1999, Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream, J Am Acad Dermatol, 41, 1002, 10.1016/S0190-9622(99)70261-6 Marks, 1993, Trends in non-melanocytic skin cancer treated in Australia: the second national survey, Int J Cancer, 53, 585, 10.1002/ijc.2910530410 Ratner, 1997, Surgical management of local disease, 664 Kuflike, 1997, Cryosurgery, 672 Greenway, 1997, Biologic response modifiers, 681